A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y<sub>12</sub> inhibitor, compared with clopidogrel in healthy humans
Joseph A. Jakubowski(Indiana Biosciences Research Institute), Kenneth J. Winters(Eli Lilly (United States)), Fumitoshi Asai(Azabu University), Nobuko Matsushima, John T. Brandt(Universitätsklinikum Würzburg), Stephen Freestone, Takashi Hirota, Hideo Naganuma(Daiichi-Sankyo (Japan))
Cited by 128
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617